PerkinElmer Stock Continues to Climb | GenomeWeb

PerkinElmer Stock Continues to Climb

Shares in PerkinElmer rose 5.54 percent for the five-day trading period ended Tuesday, continuing a steady ascent over recent weeks. The firm's shares closed at $21.15 on Tuesday, a price not reached since March 29, when PKI's shares rose as high as $21.97. Its low for the last three months was $18, which occurred on June 27. The volume of trading in the firm's shares was also relatively heavy early this week, though no news was announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.